BOSTON, May 20, 2019 /PRNewswire/ -- CSA Medical today announced the presentation of three clinical abstracts highlighting
"These studies underscore the clinical benefits of spray cryotherapy in early esophageal disease, including BE," said Wendelin Maners, CSA Medical's President. "We are excited to be sharing new data for truFreeze, which is the only cryo ablation technology with years of clinical data for addressing BE to cancer. These findings add to the growing body of data reinforcing the importance of incorporating truFreeze into the treatment regimen for BE patients."
Poster of Distinction: Liquid Nitrogen Spray Cryotherapy Eradicates Dysplasia in 87% and Intestinal Metaplasia in 65% of Patients with Barrett's Esophagus: Results of a U.S. Multicenter Registry Presented by Swathi Eluri, MD, MSCR, Assistant Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology at the University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North CarolinaSession: Barrett's Esophagus: Diagnosis, Management and SurveillanceSa1137; Type: Poster Presentation
This study evaluated rates of eradication of dysplasia and intestinal metaplasia in a real world setting in patients who were enrolled prospectively in a multicenter national registry and had undergone liquid nitrogen spray cryotherapy. Among the 210 patients, 114 met efficacy analysis criteria for complete eradication of dysplasia and intestinal metaplasia. At baseline, 53% of patients had high-grade dysplasia, 24% had low-grade dysplasia/indefinite dysplasia, 24% had intestinal metaplasia, and 3% had non-dysplastic BE. Patients received a median of three spray cryotherapy sessions. Key findings included:
Efficacy of Cryotherapy as a Primary Treatment for Dysplastic Barrett's Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-AnalysisPresented by Raseen Tariq, MD, Rochester General Hospital, Rochester, New York and Vivek Kaul, MD, Center for Advanced Therapeutic Endoscopy, Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, New YorkSession: Esophagus 1Mo1172; Type: Poster
This systematic review and meta-analysis included 20 studies, 13 of which used liquid nitrogen-based cryotherapy, 5 of which used carbon dioxide-based cryotherapy, and 2 of which used nitrous oxide-based cryotherapy as primary treatment of BE. Key findings included:
The authors concluded that cryotherapy is a safe and effective primary therapy for dysplastic BE and early esophageal neoplasia, with rates of complete eradication comparable to those reported in the literature for other ablation modalities. Accordingly, cryotherapy should be considered as primary therapy for dysplastic BE and early neoplasia when discussing ablation modalities with eligible patients.
Durability of Successful Eradication of Barrett's Esophagus with Liquid Nitrogen Spray Cryotherapy: Results of a U.S Multicenter Registry.Presented by Swathi Eluri, MD, MSCR, Assistant Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology at the University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North CarolinaSession: Barrett's Diagnosis and Therapy639; Type: Podium
This study evaluated rates of recurrence of intestinal metaplasia after complete eradication in patients who had undergone liquid nitrogen spray cryotherapy while enrolled prospectively in a multicenter national registry, thereby assessing the durability of this procedure in the setting of BE. Among the 214 patients, 114 were ³ 365 days beyond initial cryotherapy. Of these 114 patients, 74 (65%) achieved complete eradication of intestinal metaplasia; 56 of these 74 patients had post-eradication surveillance biopsies and were included in the data analysis. Key study findings included:
The authors concluded that the durability of successful treatment of intestinal metaplasia with liquid nitrogen spray cryotherapy is comparable to that of other ablation modalities.
To learn more about the truFreeze® Spray Cryotherapy System, visit https://csamedical.com/trufreeze/.
About CSA Medical and truFreeze®CSA Medical, Inc. develops and manufactures proprietary, interventional spray cryotherapy technology platforms harnessing the power of liquid nitrogen spray delivered by software driven devices with specialty catheters. Extremely cold (-196°C) liquid nitrogen spray flash freezes and destroys unwanted tissue while enabling a rejuvenative pattern of healing. CSA manufactures and distributes the truFreeze® system in the USA and is currently being utilized in over 125 leading hospitals and universities advancing therapy for patients affected by conditions such as Barrett's esophagus, esophageal cancer, and benign and malignant airway obstructions. To learn more about CSA Medical's technology, please visit www.csamedical.com.truFreeze is a registered trademark of CSA Medical, Inc.
About DDWDigestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
For further information contact: Erich Sandoval+1 917-497-2867 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/csa-medical-announces-data-presented-at-digestive-disease-week-2019-supporting-trufreeze-spray-cryotherapy-for-the-treatment-of-barretts-esophagus-300852413.html
SOURCE CSA Medical
Subscribe to our Free Newsletters!